{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:55:36Z","timestamp":1790733336055,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The 23-gene expression signature (GES) assay (myPath Melanoma) is a well-established molecular test for analyzing challenging melanocytic lesions, alongside fluorescence in situ hybridization (FISH) and single nucleotide polymorphism (SNP) array. However, routine use of these tests is often limited by high costs, long turnaround times, significant tissue requirements, and limited accessibility. This study aimed to evaluate the diagnostic concordance of PRAME immunohistochemistry (IHC) and the GES assay in difficult melanocytic lesions to determine whether PRAME IHC, widely available in pathology laboratories, could serve as a surrogate for GES. In addition, we correlated these methods with SNP array and FISH analyses, where available, to assess their diagnostic value in challenging melanocytic lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a single-institution retrospective analysis of 56 diagnostically ambiguous melanocytic lesions that underwent ancillary GES testing. All 56 cases were evaluated for PRAME IHC, while 35 had FISH results, 16 had SNP array results, and 3 had both FISH and SNP results. Two board-certified dermatopathologists independently reviewed hematoxylin and eosin (H&amp;E)-stained slides, PRAME IHC slides, and other available immunostains, along with GES results, FISH, and\/or SNP array results, classifying each lesion as benign or malignant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-six cutaneous melanocytic lesions with challenging histopathologic features were evaluated. Diagnostically ambiguous categories included dysplastic nevi versus melanoma (29 cases, 51.8%), spitzoid lesions (19 cases, 33.9%), nevoid lesions (7 cases, 12.5%), and blue nevus-like lesions (1 case, 1.8%). Of these, 38 cases (67.9%) were ultimately classified as benign, while 18 cases (32.1%) were classified as malignant.<\/jats:p>\n            <jats:p>PRAME IHC showed a significant association with malignancy, with an 83.9% concordance rate (\u03c7<jats:sup>2<\/jats:sup> = 21.37, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0001), accurately classifying 47 out of 56 cases. GES demonstrated an 82.1% concordance rate (\u03c7<jats:sup>2<\/jats:sup> = 18.68, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0001), accurately classifying 46 out of 56 cases. FISH showed a 77.1% agreement with the final diagnosis (\u03c7<jats:sup>2<\/jats:sup> = 7.63, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.005), correctly categorizing 27 out of 35 cases. Although the number of cases were relatively small, SNP array analysis correctly identified all 16 cases (\u03c7<jats:sup>2<\/jats:sup> = 16, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study supports PRAME IHC as a useful surrogate for the GES assay in the evaluation of challenging melanocytic lesions. PRAME IHC offers a cost-efficient, accessible, and practical ancillary tool that can be rapidly integrated into routine clinical practice for diagnostically ambiguous melanocytic lesions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dad.0000000000003018","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:00:34Z","timestamp":1753113634000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Diagnostic Concordance of MyPath Melanoma Assay and PRAME Immunohistochemistry in Challenging Melanocytic Lesions"],"prefix":"10.1097","author":[{"given":"Aayushma","family":"Regmi","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Parra","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravindhan","family":"Sriharan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Momtahen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cloutier","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofeng","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-652X","authenticated-orcid":false,"given":"Konstantinos","family":"Linos","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"R1-20250827","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/DAD.0000000000001713","article-title":"Concordance analysis of the 23-gene expression signature (myPath melanoma) with fluorescence in situ hybridization assay and single nucleotide polymorphism array in the analysis of challenging melanocytic lesions: results from an academic medical center","volume":"42","author":"Castillo","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"R2-20250827","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41379-018-0087-6","article-title":"Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms","volume":"31","author":"Reimann","year":"2018","journal-title":"Mod Pathol"},{"key":"R3-20250827","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/DAD.0000000000002501","article-title":"A comparison of preferentially expressed antigen in melanoma immunohistochemistry and diagnostic gene expression-profiling assay in challenging melanocytic proliferations","volume":"46","author":"Casillas","year":"2024","journal-title":"Am J Dermatopathol"},{"key":"R4-20250827","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/modpathol.2016.84","article-title":"Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions","volume":"29","author":"Minca","year":"2016","journal-title":"Mod Pathol"},{"key":"R5-20250827","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2217\/pme-2023-0110","article-title":"Diagnostic utility of the 23-gene expression profile test for an atypical intradermal melanocytic proliferation","volume":"21","author":"Marks","year":"2024","journal-title":"Per Med"},{"key":"R6-20250827","first-page":"12","article-title":"A physician's guide to the use of gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms","volume":"16","author":"Marks","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"key":"R7-20250827","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cup.12475","article-title":"Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma","volume":"42","author":"Clarke","year":"2015","journal-title":"J Cutan Pathol"},{"key":"R8-20250827","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/bmm.15.11","article-title":"Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions","volume":"9","author":"Warf","year":"2015","journal-title":"Biomark Med"},{"key":"R9-20250827","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/PAS.0000000000001492","article-title":"Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R10-20250827","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3390\/ijms25031582","article-title":"PRAME updated: diagnostic, prognostic, and therapeutic role in skin cancer","volume":"25","author":"Cassalia","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R11-20250827","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cup.13818","article-title":"PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features","volume":"47","author":"Raghavan","year":"2020","journal-title":"J Cutan Pathol"},{"key":"R12-20250827","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/DAD.0000000000001951","article-title":"Correlation of FISH and PRAME immunohistochemistry in ambiguous superficial cutaneous melanocytic proliferations","volume":"43","author":"Harvey","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"R13-20250827","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/cup.14226","article-title":"PRAME expression in melanocytic lesions of the nail","volume":"49","author":"Parra","year":"2022","journal-title":"J Cutan Pathol"},{"key":"R14-20250827","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/cup.14495","article-title":"PRAME expression in cutaneous melanoma does not correlate with disease-specific survival","volume":"50","author":"Parra","year":"2023","journal-title":"J Cutan Pathol"},{"key":"R15-20250827","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/his.14904","article-title":"Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions","volume":"83","author":"Kunc","year":"2023","journal-title":"Histopathology"},{"key":"R16-20250827","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R17-20250827","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/CMR.0000000000000626","article-title":"Diagnostic and prognostic value of glucose transporters in melanocytic lesions","volume":"29","author":"Ruby","year":"2019","journal-title":"Melanoma Res"},{"key":"R18-20250827","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jmoldx.2013.04.001","article-title":"A genome-wide high-resolution array-CGH analysis of cutaneous melanoma and comparison of array-CGH to FISH in diagnostic evaluation","volume":"15","author":"Wang","year":"2013","journal-title":"J Mol Diagn"},{"key":"R19-20250827","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0002-9440(10)63536-5","article-title":"Classifying melanocytic tumors based on DNA copy number changes","volume":"163","author":"Bastian","year":"2003","journal-title":"Am J Pathol"},{"key":"R20-20250827","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/pme-2016-0097","article-title":"The influence of a gene expression signature on the treatment of diagnostically challenging melanocytic lesions","volume":"14","author":"Cockerell","year":"2017","journal-title":"Per Med"},{"key":"R21-20250827","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-16-0958","article-title":"Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes","volume":"26","author":"Ko","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R22-20250827","first-page":"883","article-title":"Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"60","author":"Gerami","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R23-20250827","first-page":"971","article-title":"Molecular diagnosis of melanoma: current status and perspectives","volume":"66","author":"Zembowicz","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R24-20250827","first-page":"114","article-title":"Chromosomal copy number analysis in melanoma and benign melanocytic nevi by SNP array: detecting genetic events relevant to melanoma diagnosis","volume":"33","author":"North","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"R25-20250827","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R26-20250827","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/cup.13400","article-title":"A diagnostically-challenging case of melanoma ex blue nevus with comprehensive molecular analysis, including the 23-gene expression signature (myPath melanoma)","volume":"46","author":"Castillo","year":"2019","journal-title":"J Cutan Pathol"},{"key":"R27-20250827","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/DAD.0000000000002584","article-title":"Pitfalls of PRAME immunohistochemistry in a large series of melanocytic and nonmelanocytic lesions with literature review","volume":"46","author":"Turner","year":"2024","journal-title":"Am J Dermatopathol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:05:52Z","timestamp":1756307152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003018","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}